Portinari Mattia, Carcoforo Paolo
Department of Surgery, Morphology, and Experimental Medicine, S. Anna University Hospital, University of Ferrara, Ferrara, Italy.
Gland Surg. 2016 Dec;5(6):591-602. doi: 10.21037/gs.2016.11.08.
The ATA guidelines do not recommend prophylactic central compartment neck dissection in patients with T1-T2 papillary thyroid carcinoma (PTC) with no clinical evidence of lymph node metastasis, however patients' staging is recommended. Lymph node metastasis may be present also in small PTC, but preoperative ultrasound identifies suspicious cervical lymphadenopathy in 20-30% of patients. The role of sentinel lymph node biopsy (SLNB) remain open to debate. It has been shown that the identification rate of SLN in PTC patients is improved using a radiotracer compared to a dye technique. The aim of this systematic review was to evaluate the role of radioguided SLNB (rSLNB) in the treatment of PTC patients.
A systematic search was performed in the PubMed and Embase database to identify all original articles regarding the application of rSLNB in PTC patients. The primary outcome was false negative rate (FNR) of the rSLNB; the secondary outcomes were SLN intraoperative identification rate (IIR), site of lymph node metastasis, and persistent disease during follow up.
Twelve studies were included. Most of PTC patients were T1-T2. The overall SLN IIR, SLN metastatic rate, and FNR were 92.1%, 33.6%, and 25.4%, respectively. Overall, lymph node metastasis were found in the central compartment (23.0%) and in the lateral compartments (10.6%). The persistent disease in patients who underwent SLNB associated to lymph node dissection (LND) in the same compartment of the SLN regardless of the SLN status was 0.6%.
In all PTC patients, also in T1-T2 stage, due to the high FNR the SLNB performed alone should be abandoned and converted into a technique to guide the lymphadenectomy in a specific neck compartment (i.e., central or lateral) based on the radioactivity, regardless of the SLN status, for better lymph node staging and selection of patients for postoperative radioiodine ablation.
美国甲状腺协会(ATA)指南不建议对无临床淋巴结转移证据的T1 - T2期乳头状甲状腺癌(PTC)患者进行预防性中央区颈淋巴结清扫,但建议对患者进行分期。小的PTC也可能存在淋巴结转移,但术前超声在20% - 30%的患者中可发现可疑的颈部淋巴结病变。前哨淋巴结活检(SLNB)的作用仍存在争议。已表明,与染料技术相比,使用放射性示踪剂可提高PTC患者前哨淋巴结(SLN)的识别率。本系统评价的目的是评估放射性引导前哨淋巴结活检(rSLNB)在PTC患者治疗中的作用。
在PubMed和Embase数据库中进行系统检索,以识别所有关于rSLNB在PTC患者中应用的原始文章。主要结局是rSLNB的假阴性率(FNR);次要结局是SLN术中识别率(IIR)、淋巴结转移部位以及随访期间的持续性疾病。
纳入12项研究。大多数PTC患者为T1 - T2期。总体SLN IIR、SLN转移率和FNR分别为92.1%、33.6%和25.4%。总体而言,在中央区发现淋巴结转移的比例为23.0%,在侧区为10.6%。无论SLN状态如何,在与SLN同一区域进行SLNB并联合淋巴结清扫(LND)的患者中,持续性疾病的发生率为0.6%。
在所有PTC患者中,包括T1 - T2期,由于FNR较高,单独进行的SLNB应被放弃,并转换为一种基于放射性引导在特定颈部区域(即中央区或侧区)进行淋巴结清扫的技术,而不考虑SLN状态,以实现更好的淋巴结分期并为术后放射性碘消融选择合适的患者。